Strengthened the cash balance to provide runway into 2027, allowing Allarity to accelerate stenoparib's clinical development, ...

Read this article to learn how a knitting club where students and staff got together to make hats for babies in need provided ...

The current state of treatment for geographic atrophy is marked by two approved therapies that slow GA progression: ...

Pulse Biosciences, Inc. ( NASDAQ: PLSE) Q4 2024 Earnings Conference Call March 27, 2025 4:30 PM ET Philip Trip Taylor - Investor Relations Paul LaViolette - Chief Executive Officer and Co-Chairman of ...

Plus Therapeutics' Q4 2024 earnings reveal progress with REYOBIQ nearing FDA approval & CNSide's 2025 launch. Key hires & funding bolster milestones.

Oragenics, Inc. (NYSE American: OGEN), a biotechnology company focused on developing novel intranasal therapies for brain-related conditions, today ...

At least 14 million children are expected to face disruptions to essential nutrition support and services in 2025 because of ...

On track for multiple clinical updates through mid-2026, including further progress from two ongoing clinical programs and initiation of therapeutic dosing of potential new medicine, all based on our ...

If we want to turn these short-term gains into sustainable change, we must fully unleash the potential of methadone-assisted ...

A DNA nanomachine selectively targets skin cancer by detecting microRNA-7, activating phototherapy and releasing chemotherapy ...

Detailed price information for Oncotelic Therapeutics Inc (OTLC) from The Globe and Mail including charting and trades.

Non-drug approaches can help people cope with stress and despair, says an expert. Read more at straitstimes.com.